2m 2m 2m 2m 2m 2m 2m
Exozymes (EXOZ)
NASDAQ
$9.66+$0.16 (+1.68%)
Price as of Jun 03, 2026 4:10 PM EDT- $83.5MMarket Cap
- -32.96%1-Year Change
- BiotechnologyIndustry
Exozymes (EXOZ)
$9.66+$0.16 (+1.68%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | N/A N/A | N/A N/A | |
Cost of Revenue | 9.7M +63.79% | 5.9M N/A | |
Gross Profit | -9.7M +63.79% | -5.9M N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | -3.8M +99.38% | -1.9M N/A | |
Depreciation and Amortization Expense | 287,961 +7.70% | 267,382 N/A | |
Total Operating Expenses | 15.7M +57.33% | 10.0M N/A | |
Operating Profit | -9.7M +63.79% | -5.9M N/A | |
Interest Income | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 88,746 +1,398.60% | -6,834 N/A | |
Income before Taxes | -9.3M +58.05% | -5.9M N/A | |
Income Taxes | -105,205 N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | N/A N/A | N/A N/A | |
Net Income from Continuing Operations Applicable to Common | -9.3M +58.05% | -5.9M N/A | |
Basic EPS and Net Income | -1.09 +22.47% | -0.89 N/A | |
Diluted EPS and Net Income | -1.09 +22.47% | -0.89 N/A | |
Basic Weighted Average Shares | 8.4M +27.70% | 6.6M N/A | |
Diluted Weighted Average Shares | 8.4M +27.70% | 6.6M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 3.0M -68.73% | 9.7M N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 3.0M -68.73% | 9.7M N/A | |
Total Current Assets | 3.9M -63.59% | 10.8M N/A | |
Accumulated Depreciation | 1.0M +39.52% | 728,701 N/A | |
Property and Plant and Equipment and Net | 764,401 -13.38% | 882,445 N/A | |
Total Long-Term Assets | 764,401 -13.38% | 882,445 N/A | |
Total Assets | 6.0M -54.19% | 13.0M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | |
Total Current Liabilities | 1.6M +17.53% | 1.3M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 942,940 -26.35% | 1.3M N/A | |
Total Liabilities | 2.6M -1.51% | 2.6M N/A | |
Retained Earnings | -21.1M +76.67% | -11.9M N/A | |
Total Stockholders Equity | 3.4M -67.40% | 10.4M N/A | |
Total Shares Outstanding | 8.4M +0.46% | 8.4M N/A | |
Cash Flow | |||
Cash from Operating Activities | -6.5M -23.56% | -8.5M N/A | |
Capital Expenditures | 169,917 -57.14% | 396,451 N/A | |
Cash from Investing Activities | -150,218 -58.18% | -359,216 N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | -27,709 -100.15% | 18.5M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | N/A N/A | N/A N/A | |
Return on Equity | N/A N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 2.51 N/A | N/A N/A | |
Cash Ratio | 1.94 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow